Using CHARLS data from 2011 to 2020, researchers found that sleep duration and self-reported sleep quality were associated ...

Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological ...

Biotech is having a moment, and the numbers are hard to ignore. The SPDR S&P Biotech ETF (NYSEARCA:XBI) climbed 17.27% over ...

(NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important enrollment ...

Elicio Therapeutics, Inc. (Nasdaq: ELTX) ('Elicio” or the 'Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced the ...

Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...

Hospitals and health systems are rapidly adopting AI-powered tools, connected medical devices, advanced analytics and emerging biotechnology solutions. Most organizations evaluate these technologies ...

Gareth Soloway's technical market breakdown: S&P 500 trend-line test, semiconductor unwind, AI-to-biotech rotation, USD/JPY ...

Regencell Bioscience Holdings Limited (RGC) focuses on TCM-based treatments for ADHD and Autism, targeting significant ...

Hyperscalers may benefit as chip stocks struggle, according to Morgan Stanley strategists. The once-hot semiconductor trade has seen a cooling in the last couple of weeks, which is not only likely to ...

Hyperscalers may benefit as chip stocks struggle, according to Morgan Stanley strategists. The once-hot semiconductor trade has seen a cooling in the last couple of weeks, which is not only likely to ...

FHLC is the far cheaper option for long-term investors, charging an expense ratio of just 0.08% compared to BBH's 0.35%. FHLC also pays a higher trailing dividend yield of 1.40%, nearly 0.9 percentage ...